STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.
Simon Papillon-CavanaghParul DoshiRadu DobrinJoseph SzustakowskiAlice M WalshPublished in: ESMO open (2021)
Our results show that STK11-KEAP1 mutations are prognostic, not predictive, biomarkers for anti-PD-1/anti-PD-L1 therapy.